Nuvation Bio Inc. completes acquisition of AnHeart Therapeutics Ltd. to enhance its oncology pipeline
Nuvation Bio Inc. completes acquisition of AnHeart Therapeutics Ltd. to enhance its oncology pipeline
04/10/24, 8:07 PM
Location
new yorknew yorkIndustry
biopharma
therapeutics
biotechnology
health care
biopharma
therapeutics
pharmaceutical
biotechnology
health care
Nuvation Bio Inc., a late-stage global biopharmaceutical company, has successfully completed the acquisition of AnHeart Therapeutics Ltd. This acquisition transforms Nuvation Bio into a well-capitalized, late-stage, global oncology company, expanding its pipeline and positioning it to become a commercial organization.
Company Info
Location
New York, New York, United States
Company info
Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio’s proprietary portfolio includes mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco. For more information, please visit www.nuvationbio.com.